Coagulation factor XIII A chain Antibody [F13A1/1683]

Primary Antibodies

Aliquot and Store at 2-8˚ C. Avoid freez-thaw cycles.

Factor XIIIa has been identified in platelets, megakaryocytes, and fibroblast-like mesenchymal or histiocytic cells in the placenta, uterus, and prostate, monocytes and macrophages and dermal dendritic cells. Anti-Factor XIIIa has been found to be useful in differentiating between dermatofibroma (almost all cases are positive), dermatofibrosarcoma protuberans (-/+) and desmoplastic malignant melanoma (-). Anti-Factor XIIIa positivity is also seen in capillary hemagioblastoma, hemangioendothelioma, hemangiopericytoma, xanthogranuloma, xanthoma, hepatocellular carcinoma, glomus tumor, and meningioma.

None

0.2 mg/mL

ELISA: order the BSA-free formulation for coating
Immunofluorescence: 1-2 ug/ml
Flow Cytometry: 0.5-1 ug/million cells in 0.1ml
Immunohistochemistry (FFPE): 1-2 ug/ml for 30 min at RT
Prediluted IHC only format: incubate for 30 min at RT (1)
Titering of the Factor XIIIa antibody may be required for optimal performance.

1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

Monoclonal

Homo sapiens

Optimal dilutions for each application to be determined by the researcher